skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination

Review

(2159) Views  (597) Full article downloads

Authors: Giuseppe Derosa, Sibilla AT Salvadeo

Published Date May 2010 Volume 2010:3 Pages 21 - 30
DOI: http://dx.doi.org/10.2147/IBPC.S6081

Giuseppe Derosa, Sibilla AT Salvadeo

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Abstract: Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, or in combination with other drugs, for the treatment of hypertension in many countries worldwide. Data in the literature suggest that irbesartan is effective for reducing blood pressure over a 24-hour period with once-daily administration, and slows the progression of renal disease in patients with hypertension and type 2 diabetes. Furthermore, irbesartan shows a good safety and tolerability profile, compared with angiotensin II inhibitors and other angiotensin II type 1 receptor antagonists. Thus, irbesartan appears to be a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy. Irbesartan has an inhibitory effect on the pressor response to angiotensin II and improves arterial stiffness, vascular endothelial dysfunction, and inflammation in hypertensive patients. There has been considerable interest recently in the renoprotective effect of irbesartan, which appears to be independent of reductions in blood pressure. In particular, mounting data suggests that irbesartan improves endothelial function, oxidative stress, and inflammation in the kidneys. Recent studies have highlighted a possible role for irbesartan in improving coronary artery inflammation and vascular dysfunction. In this review we summarize and comment on the most important data available with regard to antihypertensive effect, endothelial function improvement, and cardiovascular risk reduction with irbesartan.

Keywords: blood pressure, hypertension, endothelial function, irbesartan, antihypertensive drugs, combination therapy






 

Other articles by Professor Giuseppe Derosa



Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
De-stiffening drug therapy and blood pressure control
Evidence-based approach for managing hypertension in type 2 diabetes
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness
Impact of telmisartan in modifying vascular risk
Long-term use and tolerability of irbesartan for control of hypertension
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University